检索结果-南通市图书馆

帕博利珠单抗单药治疗PD-L1阳性伴脑转移的非小细胞肺癌患者的疗效：KEYNOTE-001、010、024和042研究的汇总分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国肺癌杂志 2022年第9期25卷 701-712页

作者： Aaron S. MANSFIELD Roy S. HERBST Gilberto de CASTRO Jr. Rina HUI nir peled Dong-Wan KIM Silvia NOVELLO Miyako SATOUCHI Yi-Long WU Edward B.GARON Martin RECK Andrew G.ROBINSON Ayman SAMKaRI Bilal PIPERDI Victoria EBIANA Jianxin LIN Tony S.K.MOK 黎扬斯 Division of Medical Oncology Mayo Clinic Yale Comprehensive Cancer Center Yale University School of Medicine Instituto do Cancer do Estado de S?o Paulo Westmead Hospital and the University of Sydney Soroka Cancer Center Ben Gurion University Seoul National University Hospital Seoul National University College of Medicine Azienda Ospedaliero-Universitaria San Luigi Gonzaga University of Turin Hyogo Cancer Center Guangdong Lung Cancer Institute Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences David Geffen School of Medicine at the University of California Los Angeles Lung Clinic Grosshansdorf Airway Research Center North German Center of Lung Research Cancer Centre of Southeastern Ontario at Kingston General Hospital Merck & Co. Inc. State Key Laboratory of Translational Oncology Chinese University of Hong Kong 广东省人民医院广东省人民医院肿瘤医院广东省肺癌研究所

背景与目的我们回顾性评估了程序性死亡配体1（programmed death ligand 1, PD-L1）阳性非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的预后，以比较基线（即入组时）脑转移与帕博利珠单抗及化疗的疗效关系。方法我们汇总... 详细信息

背景与目的我们回顾性评估了程序性死亡配体1（programmed death ligand 1, PD-L1）阳性非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的预后，以比较基线（即入组时）脑转移与帕博利珠单抗及化疗的疗效关系。方法我们汇总分析了KEYNOTE-001（NCT01295827）、KEYNOTE-010（NCT01905657）、KEYNOTE-024（NCT02142738）和KEYNOTE-042（NCT02220894）研究中既往接受过治疗或未接受过的PD-L1阳性[肿瘤细胞阳性比例评分（tumor proportion score, TPS）≥1%]的晚期或转移性NSCLC患者的数据。患者接受帕博利珠单抗（2 mg/kg,10 mg/kg，或每3周200 mg或每2周10 mg/kg）治疗；而化疗是除KEYNOTE-001外所有研究的对照组。所有研究都纳入了既往接受过治疗的稳定脑转移的患者。结果共计纳入3,170例患者，基线时，293例（9.2%）患者伴有脑转移，而2,877例（90.8%）是无脑转移患者；数据截止时，中位（范围）随访时间为12.9（0.1-43.7）个月。与化疗相比，帕博利珠单抗可改善基线伴有脑转移及无脑转移患者的总生存期：PD-L1 TPS≥50%[分别为0.67（95%CI:0.44-1.02）和0.66（95%CI:0.58-0.76）]和PD-L1 TPS≥1%[分别为0.83（95%CI:0.62-1.10）和0.78（95%CI:0.71-0.85）]。无论是否有脑转移，与化疗相比，接受帕博利珠单抗治疗患者的无进展生存期更长，客观缓解率更高，缓解持续时间更长。在脑转移患者中，帕博利珠单抗与化疗的治疗相关不良事件发生率分别为66.3%和84.4%，在无脑转移患者中分别为67.2%和88.3%。结论对于既往未接受治疗或接受过治疗的PD-L1阳性晚期/转移性NSCLC患者，无论基线时是否存在治疗后稳定的脑转移，帕博利珠单抗单药治疗显示出明显的疗效改善，且与化疗相比，不良事件更少。

关键词：帕博利珠单抗脑转移化疗非小细胞肺癌 PD-L1

ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2020年第6期11卷 365-370页

作者： Alexander Yakobson Tal Mor Levitas Dina Laila C. Roisman Daniel Levin Wafeek Alguayn Sara Morgenstern Keren Rouvinov nir peled Waleed Kian The Legacy Heritage Oncology Center & Dr. Larry Norton Institute Soroka Medical Center & Ben-Gurion University Beer-Sheva Israel Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel Faculty of Health Sciences Ben-Gurion University of the Negev Beer-Sheva Israel Rabin Medical Center Beilinson Campus Petah Tikva Israel

ROS1 oncogenic fusion is reported to be 1% - 2% of non-small cell lung cancers (NSCLCs) of the adenocarcinoma subgroup. Meanwhile, there are no records of squamous cell cancer patients with tumors harboring ROS1 fusions. The Foundation Medicine database indicates a frequency of ROS1 rearrangements is 0.2% among squamous NSCLC. Crizotinib is known to be very effective in these patients. Here we present a non-smoker patient who had pure squamous NSCLC that was treated by combinational immunotherapy under a clinical trial and progressed after 2 cycles. Surprisingly, comprehensive genomic profiling detected a rare oncogenic EZR-ROS1 fusion, and the patient was treated by crizotinib with a significant response within 6 weeks. To date, the patient has been on therapy for 42 months and has achieved a complete metabolic response.

关键词： ROS1 Crizotinib Squamous Cell Lung Cancer Immunotherapy Non-Small Cell Lung Cancer

Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Therapy 2013年第8期4卷 54-58页

作者： Dekel Shlomi Amir Onn Maya Gottfried Jair Bar Haim Biran Maya Ilouze Addie Dvir Hovav Nechushtan Lior Soussan-Gutman nir peled Oncology Department Meir Medical Center Kfar Saba Israel Oncotest-TEVA Teva Pharmaceutical Industries LTD. Shoham Israel Pulmonary-Oncology Unit Chaim Sheba Medical Center Tel Hashomer Israel Sharett Institute of Oncology Hadassah He- brew University Medical Center Jerusalem Israel.

Background: In the last decade, the search for gene mutations in lung cancer has been constantly growing. EGFR, KRAS mutations and, recently, the EML4-ALK fusion can guide the selection of treatment for patients who carry a specific mutation. Methods: During 2010-2011, EML4-ALK fusion test has been performed in Israel, mostly for wild type EGFR non-squamous NSCLC patients based on fluorescent in-situ hybridization (FISH) technique to detect EML4-ALK rearrangements. Results: Between January 2010 and December 2011, 3341 patients were diagnosed with lung cancer in Israel. Of the 2997 patients with NSCLC 687 had squamous cell carcinoma and 2310 had non-squamous NSCLC. This study focused on available 125 non-squamous NSCLC cases in which analysis for EML4-ALK rearrangement was available. All were negative for EGFR mutation. Nineteen (15.2%) were found positive for the fusion, a figure 2 - 10 times higher compared with previously reported findings. The EML4-ALK fusion was significantly more prevalent in younger male patients (52.1 vs. 61.3 years, p = 0.049), in whom every additional year reduced the chance to find the fusion by 7% [CI = 0.93 (0.88 - 0.99), p = 0.03]. Conclusions: A stepwise approach based on histology and prior EGFR analysis to detect EML4-ALK fusion is highly efficient with a related increased yield of detection. We recommend testing patients with non-squamous cell lung carcinoma after ruling out an EGFR mutation. The chance to find the ALK fusion is significantly greater in younger men.

关键词： Lung Cancer EML4-ALK Gene Mutation EGFR Histology

The nature and sources of international variation in formal institutions related to initial coin offerings:preliminary findings and a research agenda

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Financial Innovation 2023年第1期9卷 281-318页

作者： nir Kshetri The University of North Carolina at Greensboro GreensboroUSA

As prior researchers have suggested,a firm’s success in an international market depends on how well its strategy fits the nonmarket environment,such as formal *** paper examines the determinants of formal institutions around new areas of economic ***,we propose a framework for understanding how the quality of formal institutions in promoting entrepreneurship drives the focus of such institutions concerning initial coin offering(ICO),which is emerging as a popular fundraising *** paper uses inductive analysis to examine how nonmarket factors—such as a jurisdiction’s tax haven nature,regulators’perceptions of ICOs as threats to national or political interests,and trade and industry associations—might moderate the relationship between the quality of institutions and the focus of such institutions regarding *** of this study’s key findings is that an economy’s quality of entrepreneurship-related institutions,perceived threats to national/political interests,and tax haven nature lead to different policy ***,regulators assign different importance when promoting crypto-entrepreneurship and dealing with associated *** focusing mainly on promoting crypto-ventures have taken measures to enrich the blockchain ecosystem and provided tax and non-tax incentives to attract such *** focusing mainly on dealing with crypto-venture risks rely on a regulatory sandbox and close regulatory monitoring of such ventures.

关键词： Blockchain Cryptocurrencies Crypto-ventures Initial coin offerings Regulatory sandboxes Tax havens

Systems-based approaches to study immunometabolism

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2022年第3期19卷 409-420页

作者： Vinee Purohit Allon Wagner nir Yosef Vijay K.Kuchroo Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases Brigham and Women’s HospitalHarvard Medical SchoolBostonMA02115USA Broad Institute of MIT and Harvard CambridgeMA02141USA Department of Electrical Engineering and Computer Science University of CaliforniaBerkeleyCA94720USA Center for Computational Biology University of CaliforniaBerkeleyCA94720USA

Technical advances at the interface of biology and computation,such as single-cell RNA-sequencing(scRNA-seq),reveal new layers of complexity in cellular *** emerging area of investigation using the systems biology approach is the study of the metabolism of immune *** diverse spectra of immune cell phenotypes,sparsity of immune cell numbers in vivo,limitations in the number of metabolites identified,dynamic nature of cellular metabolism and metabolic fluxes,tissue specificity,and high dependence on the local milieu make investigations in immunometabolism challenging,especially at the single-cell *** this review,we define the systemic nature of immunometabolism,summarize cell-and system-based approaches,and introduce mathematical modeling approaches for systems interrogation of metabolic changes in immune *** close the review by discussing the applications and shortcomings of metabolic modeling *** systems-oriented studies of metabolism expected to become a mainstay of immunological research,an understanding of current approaches toward systems immunometabolism will help investigators make the best use of current resources and push the boundaries of the discipline.

关键词： Immunometabolism Metabolic techniques GSMM Metabolic modeling Systems biology

Fetal Growth in Twin Pregnancies and the Choice of Growth Chart

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Maternal-Fetal Medicine 2022年第4期4卷 234-237页

作者： nir Melamed Liran Hiersch Division of Maternal-Fetal Medicine Department of Obstetrics and GynecologySunnybrook Health Sciences CentreToronto M5N 3M5ONCanada Department of Obstetrics and Gynaecology Lis Maternity HospitalSourasky Medical Center and Sackler Faculty of MedicineTel Aviv UniversityTelAviv 6423906Israel

Background Twin gestations are associated with an increased risk of pregnancy complications such as preterm birth,hypertensive disorders of pregnancy(HDP),and fetal growth restriction(FGR).1-5 Twin pregnancies are characterized by.a slower fetal growth compared to singletons during the third *** mechanisms underlying this phenomenon and whether it represents a pathological FGR or a harmless physiologic adaptation are currently *** important implication of these questions relates to the growth charts that should be used by care providers to monitor growth of *** the slower growth represents a pathology,then singleton growth charts should be used to identify the small twin fetus which may be at an increased risk of mortality and ***,however,the slower growth of twins reflects a benign adaptation,then twin-based charts may be preferable to avoid overdiagnosis of FGR in twin gestations.

关键词： fetal diagnosis Twin

维普期刊数据库

Stepping up to meet the challenge of freezing of gait in Parkinson’s disease

在线全文

学校读者我要写书评

暂无评论

Translational Neurodegeneration 2022年第1期11卷 589-600页

作者： Simon Lewis Stewart Factor nir Giladi Alice Nieuwboer John Nutt Mark Hallett ForeFront Parkinson’s Disease Research Clinic Brain and Mind CentreSchool of Medical SciencesUniversity of SydneySydneyNSWAustralia Jean and Paul Amos Parkinson’s Disease and Movement Disorders Program Emory University School of MedicineAtlantaGAUSA Movement Disorders Unit Department of NeurologyTel-Aviv Sourasky Medical CenterSackler School of Medicine and Sagol School of NeuroscienceTel Aviv UniversityTel AvivIsrael Department of Rehabilitation Sciences KU LeuvenLeuvenBelgium Movement Disorder Section Department of NeurologyOregon Health&Science UniversityPortlandORUSA Human Motor Control Section National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaMDUSA.

There has been a growing appreciation for freezing of gait as a disabling symptom that causes a significant burden in Parkinson’s disease. Previous research has highlighted some of the key components that underlie the phenomenon, but these reductionist approaches have yet to lead to a paradigm shift resulting in the development of novel treatment strategies. Addressing this issue will require greater integration of multi-modal data with complex computational modeling, but there are a number of critical aspects that need to be considered before embarking on such an approach. This paper highlights where the field needs to address current gaps and shortcomings including the standardization of definitions and measurement, phenomenology and pathophysiology, as well as considering what available data exist and how future studies should be constructed to achieve the greatest potential to better understand and treat this devastating symptom.

关键词： Freezing of gait Computational modeling Standardized definitions and assessments Novel paradigms Phenomenology Pathophysiology Treatment

马普街5号住宅大楼——以色列特拉维夫-雅法

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界建筑导报 2023年第3期38卷 84-87页

作者： Gidi Bar Orian Kfir peled nir Ovadia Noam Elkabetz Amit Geron(摄影) Bar Orian建筑师事务所

马普街5号是一栋方形的新建住宅大楼,位于特拉维夫白城中心马普街与Yehoash街道的拐角处--白城被联合国教科文组织列入世界遗产名录,因该地大量的包豪斯(Bauhaus)和折中主义建筑风格的建筑物而享誉世界。该建筑位于特拉维夫最理想的地... 详细信息

马普街5号是一栋方形的新建住宅大楼,位于特拉维夫白城中心马普街与Yehoash街道的拐角处--白城被联合国教科文组织列入世界遗产名录,因该地大量的包豪斯(Bauhaus)和折中主义建筑风格的建筑物而享誉世界。该建筑位于特拉维夫最理想的地区之一,其地块在大小和形状上(1.3德南(dunam:以色列单位))都异于寻常,是当地普通地块的三倍大,与特拉维夫地中海海滨大道相距约200米(600英尺)--正是在这样一个被忽视的空地上,Bar Orian接受了委托,要在此处构思和规划建设一栋新建筑。这片弃用的地块反而为其提供了一个极佳的机会,得以展示一栋向特拉维夫中东-地中海构造风格致敬的建筑,同时创造了一种新的当代视觉呈现。

关键词：建筑风格住宅大楼世界遗产名录海滨大道包豪斯构造风格联合国教科文组织马普

维普期刊数据库

Inhibition of FLT3:A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia

在线全文

学校读者我要写书评

暂无评论

Engineering 2021年第10期7卷 1354-1368页

作者： Meira Yisraeli Salman Jacob M.Rowe nir Weigert Department of Hematology Shaare Zedek Medical CenterJerusalem 9103102Israel Department of Hematology and Bone Marrow Transplantation Rambam Medical CenterHaifa 3109601Israel Technion—Israel Institute of Technology Haifa 3200003Israel

Modern therapy of acute myeloid leukemia(AML)began in 1973 with the first report of the successful combination of daunorubicin and cytarabine,which led to complete remission in approximately 45%of *** AML diagnosis was dependent on morphology,aided initially only by *** acute lymphoblastic leukemia(ALL),immunophenotyping offered little in the diagnosis of AML,at least during the 1970s and *** advent of reliable cytogenetics changed the entire prognostic outlook of *** karyotypic analysis,different groups of AML could be classified and stratified for various *** mutational profiling was a major advance in further categorizing AML patients,aided by the immunophenotypic identification of antigenic markers on the *** these advances were occurring as the understanding of the importance of the tumor burden—known as minimal residual disease(MRD)—became crucial for the management of AML *** efficacy of MRD has rapidly progressed in the past decade,from a specificity of 103 with immunophenotyping to 104 with polymerase chain reaction(PCR),which is only appropriate for some patients with AML,and finally to 105 or even 106 cells with the extraordinary sensitivity of next-generation sequencing(NGS).All of these advances have promoted the concept of personalized medicine,which has led to the advent of targeted agents that can accurately be used for specific diagnostic *** can be predicted and measured *** targeted agents have now become a cornerstone in the management of AML,increasing effi-cacy and dramatically reducing *** focus of this review is on one of the most well-studied targeted agents in AML:the FMS-like tyrosine kinase 3(FLT3)inhibitors,which have impacted the prognostication and therapeutics of *** review selectively discusses the FLT3 inhibitors in detail,as a model for the other burgeoning targeted agents that have already been approved,as well as tho

关键词： AML Targeted therapy FLT3 inhibitors Midostaurin Gilteritinib Quizartinib Sorafenib

维普期刊数据库